Hot flashes are one of the most common and most wearing effects of breast cancer treatment. Tamoxifen and aromatase inhibitors both bring them on, often more intensely than natural menopause, and the usual fix, estrogen, is generally off-limits after a hormone-sensitive cancer. That combination leaves a lot of women managing intense symptoms with little guidance.

There are good non-hormonal options. The key is choosing one that does not interfere with your cancer treatment, and that depends on which medicine you take.

Why Tamoxifen Changes the Decision

Tamoxifen does not work as you swallow it. Your liver converts it, using an enzyme called CYP2D6, into an active form called endoxifen, which is what actually blocks estrogen at the tumor. Anything that strongly blocks that enzyme can lower your endoxifen level and, in theory, make tamoxifen work less well.

This is not hypothetical. A large population study found that women taking both tamoxifen and paroxetine, a strong blocker of that enzyme, had a higher risk of dying from breast cancer, and the risk rose with more overlap between the two (Kelly, BMJ 2010). Paroxetine's own FDA label now advises weighing the benefit against the risk of reducing tamoxifen's effect, and considering avoiding the combination.

The practical rule that follows is simple: if you take tamoxifen, avoid paroxetine and fluoxetine for hot flashes. There are better choices.

Aromatase inhibitors, anastrozole, letrozole and exemestane, work differently and do not depend on that enzyme. If you take one of those rather than tamoxifen, the enzyme issue does not apply, and the options below are all open.

The Options That Are Safe With Tamoxifen

Venlafaxine is the one most cancer specialists reach for first. It is an SNRI that barely affects the CYP2D6 enzyme, so it does not get in tamoxifen's way, and it is described in the pharmacology literature as the preferred antidepressant for hot flashes in women on tamoxifen (Desmarais, Journal of Clinical Psychiatry 2009). It also has strong evidence for hot flashes in general, cutting them by roughly half (Joffe, JAMA Internal Medicine 2014). The dose is 75 mg a day.

Oxybutynin is the other strong choice, and it has something unusual going for it: the main trial deliberately enrolled women who could not take estrogen, and about two thirds of them were on tamoxifen or an aromatase inhibitor. At 5 mg twice a day it cut weekly hot flashes by 7.5 against 2.6 for placebo (Leon-Ferre, ACCRU trial, JNCI Cancer Spectrum 2020). It is a bladder medicine used off-label here, neither a hormone nor an antidepressant, and it does not touch the tamoxifen enzyme. The main downsides are dry mouth and constipation, and it is not used if you have narrow-angle glaucoma or trouble emptying your bladder.

Both are inexpensive generics and neither needs routine blood tests.

What About the Newer Drugs?

A drug called elinzanetant (Lynkuet), approved in October 2025, was studied specifically in women getting hot flashes from breast cancer treatment, and it worked well, cutting hot flashes by about three to four more per day than placebo, with no liver-test monitoring required (Cardoso, New England Journal of Medicine 2025). It is the best-evidenced option for exactly this situation. The catch is cost: it is brand-only at over 600 dollars a month, and its savings programs do not apply if you pay cash. The related drug fezolinetant (Veozah) carries a boxed warning for liver injury and needs repeated blood tests. Both are worth raising with your oncology team; neither fits a low-cost online service today.

A Note on Vaginal Symptoms

Hot flashes are one problem; vaginal dryness and painful sex are another, and breast cancer treatment drives both. The vaginal symptoms need a different approach, and one oral drug sometimes mentioned, ospemifene, is specifically labeled not for use in women with a history of breast cancer. That is a conversation for your oncology team, who can weigh local, low-absorption options case by case.

The Takeaway

If you take tamoxifen, venlafaxine and oxybutynin are the safe, effective, low-cost choices, and paroxetine is the one to avoid. If you take an aromatase inhibitor, the enzyme issue does not apply and your options are wider. Either way, loop in your oncology team, since they know your full picture.

Reviewed By

[Reviewed by: clinician name, credential. Last reviewed: date.]

Looking for hot flash relief that is safe with your breast cancer treatment? See the non-hormonal options and start an intake. The questions ask about tamoxifen and route you to the right choice, and a licensed clinician reviews everything.

This article is for education and is not a substitute for individual medical advice from your own clinician or oncology team. Talk with the team managing your cancer treatment before starting or changing a medication.